^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sabestomig (AZD7789)

    i
    Other names: AZD7789, AZD 7789
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    PD1 inhibitor, TIM-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11d
    PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Presage Biosciences
    New P1 trial
    |
    Keytruda (pembrolizumab) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    1m
    A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (clinicaltrials.gov)
    P1/2, N=232, Recruiting, AstraZeneca | Trial completion date: Apr 2025 --> Jul 2025 | Trial primary completion date: Jan 2025 --> Jul 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 expression
    |
    sabestomig (AZD7789)
    3ms
    A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (clinicaltrials.gov)
    P1/2, N=192, Recruiting, AstraZeneca | N=147 --> 192
    Enrollment change • Metastases
    |
    PD-L1 expression
    |
    sabestomig (AZD7789)
    4ms
    TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1; Phase classification: P1b --> P1 | N=232 --> 321
    Combination therapy • Enrollment change • Phase classification • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    carboplatin • Imfinzi (durvalumab) • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    5ms
    Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=240, Recruiting, AstraZeneca | N=80 --> 240
    Enrollment change • Metastases
    |
    CLDN18 (Claudin 18)
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • AZD0901 • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    5ms
    Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Recruiting, AstraZeneca | Trial completion date: Feb 2026 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    sabestomig (AZD7789)
    6ms
    Safety and Preliminary Efficacy of Sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-(L)1 Therapy (ASH 2023)
    Sabestomig is intravenously infused over 1 hour following pretreatment with diphenhydramine and acetaminophen every 3 weeks, with planned doses ranging from 2 to 2000 mg across 8 cohorts (A1–A8); cohorts A1 to A4 (2, 7, 22.5 or 75 mg) follow an accelerated titration design with a single patient treated at each dose level, while cohorts A5 to A8 (225–2000 mg) follow a modified toxicity probability interval-2 algorithm. Early efficacy data at 750 mg is encouraging with objective responses in 3/3 patients who had their first disease assessment, including those who were anti-PD-1 refractory or who relapsed on treatment. Updated data will be presented from ongoing and subsequent patients treated during dose escalation with doses of up to 2000 mg.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    HAVCR2 expression
    |
    sabestomig (AZD7789)
    9ms
    Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy (ESMO 2023)
    Conclusions AZD7789 has manageable safety and shows preliminary efficacy at tolerable doses. Evaluation is ongoing in immunotherapy-naive pts with NSCLC and pts with acquired resistance to immunotherapy.
    Clinical
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    sabestomig (AZD7789)
    10ms
    A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (clinicaltrials.gov)
    P1/2, N=152, Recruiting, AstraZeneca | N=81 --> 152
    Enrollment change • Metastases
    |
    PD-L1 expression
    |
    sabestomig (AZD7789)
    11ms
    Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Recruiting, AstraZeneca | Trial completion date: Sep 2025 --> Feb 2026
    Trial completion date
    |
    sabestomig (AZD7789)
    12ms
    Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Recruiting, AstraZeneca | Trial primary completion date: Sep 2025 --> May 2024
    Trial primary completion date
    |
    sabestomig (AZD7789)
    over1year
    Generation of AZD7789, a novel PD-1 and TIM-3 targeting bispecific antibody, which binds to a differentiated epitope of TIM-3 (SITC 2022)
    AZD7789 is being tested in IO pretreated patients with NSCLC ( NCT04931654 ) and cHL ( NCT05216835 ). Trial Registration NCT04931654; NCT05216835
    PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    HAVCR2 expression
    |
    sabestomig (AZD7789)